Agora Labs raises €4.3m to federate hospital data across borders
Agora Labs, a Rome-founded deep-tech company, has closed a €4.3 million funding round led by Italian venture capital firm P101, with co-investment from Infinite Five, a holding company active in martech, data analysis and robotics. The capital will fund international expansion across the EU, the US, the Middle East and India, as well as a hiring push of around 20 technical and commercial staff. The company's ambition: to double its hospital network from 50 facilities to 100.
The story is not simply a health-tech funding round. It sits at the intersection of three converging pressures: the global scramble to unlock clinical data for AI model training, the tightening of patient-privacy regulation across multiple jurisdictions, and the growing appetite among pharmaceutical companies and regulators for Real World Evidence (RWE) to supplement traditional clinical trials. Agora Labs is building the connective tissue between all three.
How the infrastructure works
The core architecture is deliberately decentralised. Rather than moving patient data to a centralised repository, Agora Labs installs an on-premise GPU node, supplied by NVIDIA, at each participating hospital. Specialised large language models structure and standardise the raw clinical data locally. The data is then anonymised through what the company describes as irreversible mathematical processes, designed to remain secure even against quantum-computing-era decryption techniques. Only model outputs and inferences travel across the network, not the underlying records. This federated learning approach means hospitals retain sovereignty over their data while still contributing to multicentre research at international scale.
The network already spans institutions from Harvard Medical School to Milan's San Raffaele Hospital. Live projects include a Saudi Arabian initiative integrating genetic, clinical and radiological data to build predictive models for type 1 and type 2 diabetes complications. That project alone illustrates the macro opportunity: Gulf health systems, under-served by Western clinical trial populations, are actively seeking data infrastructure that can model their own patient demographics.
The convergence read-across
The RWE market context amplifies the investment thesis. The global market for RWE solutions is estimated to grow from $5.4 billion in 2025 to $10.8 billion by 2030, according to figures cited in the release. That trajectory is being driven partly by regulatory demand, with agencies including the FDA and EMA increasingly accepting RWE to support drug approvals and label expansions, and partly by the AI training data problem: healthcare AI models are only as good as the clinical data they can access, and most of that data remains locked inside individual hospital IT systems in fragmented, unstructured form.
For pharmaceutical companies, Agora Labs' federated model offers something structurally different from existing data-brokerage arrangements: a network effect that grows more valuable with each new hospital node, combined with a privacy architecture that does not require patients or regulators to accept data leaving the originating institution. That combination is directly relevant to the EU's evolving European Health Data Space regulation, which is pushing towards cross-border clinical data access while preserving GDPR-grade protections.
The capital-allocation angle is also worth noting. P101 now counts four health-tech companies in its portfolio, representing more than 20% of its Programma 103 fund by investment count. Italian venture capital is not typically associated with deep-tech health infrastructure at global scale, but P101's integration of PranaVentures in 2026 and its links to EU-backed funding mechanisms, including the InvestEU Fund and CDP Venture Capital's Digital Transition programme, give it a structural advantage in sourcing deals that straddle European regulatory complexity and sovereign-capital mandates. This is not a bilateral VC story; it is a model for how European public-private capital stacks are starting to back infrastructure plays that would otherwise require US or Gulf anchor investors.
For cross-sector investors watching the convergence of AI compute, life sciences data, and regulatory arbitrage, Agora Labs is a small but structurally instructive bet. The question the next funding round will need to answer is whether a federated-node model can scale commercially fast enough to outpace the larger US and UK health-data platforms already competing for pharmaceutical R&D budgets.